Based on significant growth and productivity as a program in development during the last funding period, Neuro-oncology (NO) was recently elevated from an HICCC Program in Development to a Full Program. The broad goal of the NO Program is to optimize diagnostic and therapeutic strategies for brain tumors by applying the expertise of a multidisciplinary team towards translating knowledge of brain tumor systems biology, genetics and cell biology. This goal is motivated by the recognition that molecular/genetic insight into brain tumors has the potential for development of individualized patient-specific treatment strategies. To advance its goal, the NO Program is organized around three interactive themes: 1) expanded novel tumor target discovery based on greater understanding of regulatory networks, cellular transformation and micro-environmental influences;2) improved translational therapeutic studies through development of preclinical animal models, high throughput drug screening and novel drug delivery strategies;and 3) refinement of a multidisciplinary clinical center with advanced tissue banking and database collection to facilitate molecularly stratified clinical trials. Major strengths of the program include expertise in systems biology with demonstrated translational application, innovative stem cell/progenitor cell biologists focusing on therapeutic target discovery in brain tumors, and innovative leaders in the fields of animal models of glioma and advanced drug delivery strategies with demonstrated abilities to translationally exploit therapeutic testing. Additionally, the Program maintains a robust brain tumor tissue bank specifically designed to facilitate the translation basic science discoveries into preclinical models and comprehensive clinical trials with correlative molecular pathological studies. The Program has fostered these goals through organization of collaborative investigators, recruitment of new members, support of intra-programmatic meetings and use of shared tissue bank/database resources. The NO program consists of 20 Program members (14 full) representing 9 departments within the College of Physicians and Surgeons and combining a spectrum from basic science to clinical proficiency. During the last budget period (July 1, 2012 - June 30, 2013), the NO Program received a total of $4.7M (direct costs) in cancer-relevant grant support, including $1.5M (direct costs) in NCI funding, $1.9M (direct costs) in other peer reviewed cancer-related support and $1.2M (direct costs) in cancer-relevant non-peer reviewed funding. There were a total of 173 Program publications from 2008 to the present, of which 32% were intra-programmatic and 20% were inter-programmatic and/or collaborative with investigators in other institutions;12% were published in journals with Impact Factor >10, and 5% in journals with Impact Factor > 20.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA013696-40
Application #
8753114
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-07-04
Project End
2019-06-30
Budget Start
2014-07-17
Budget End
2015-06-30
Support Year
40
Fiscal Year
2014
Total Cost
$33,319
Indirect Cost
$12,495
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Proto, Jonathan D; Doran, Amanda C; Gusarova, Galina et al. (2018) Regulatory T Cells Promote Macrophage Efferocytosis during Inflammation Resolution. Immunity 49:666-677.e6
Hernandez, Celine; Huebener, Peter; Pradere, Jean-Philippe et al. (2018) HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis. J Clin Invest 128:2436-2451
Lee, Younghyun; Pujol Canadell, Monica; Shuryak, Igor et al. (2018) Candidate protein markers for radiation biodosimetry in the hematopoietically humanized mouse model. Sci Rep 8:13557
Kraakman, Michael J; Liu, Qiongming; Postigo-Fernandez, Jorge et al. (2018) PPAR? deacetylation dissociates thiazolidinedione's metabolic benefits from its adverse effects. J Clin Invest 128:2600-2612
Cui, Xuan; Jauregui, Ruben; Park, Karen Sophia et al. (2018) Multimodal characterization of a novel mutation causing vitamin B6-responsive gyrate atrophy. Ophthalmic Genet 39:512-516
Evans, Lucy P; Newell, Elizabeth A; Mahajan, MaryAnn et al. (2018) Acute vitreoretinal trauma and inflammation after traumatic brain injury in mice. Ann Clin Transl Neurol 5:240-251
Dieck, Chelsea L; Tzoneva, Gannie; Forouhar, Farhad et al. (2018) Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia. Cancer Cell 34:136-147.e6
Nathan, J; Ruscitto, A; Pylawka, S et al. (2018) Fibrocartilage Stem Cells Engraft and Self-Organize into Vascularized Bone. J Dent Res 97:329-337
Kratchmarov, Radomir; Viragova, Sara; Kim, Min Jung et al. (2018) Metabolic control of cell fate bifurcations in a hematopoietic progenitor population. Immunol Cell Biol 96:863-871
Sengillo, Jesse D; Lee, Winston; Bakhoum, Mathieu F et al. (2018) CHOROIDEREMIA ASSOCIATED WITH A NOVEL SYNONYMOUS MUTATION IN GENE ENCODING REP-1. Retin Cases Brief Rep 12 Suppl 1:S67-S71

Showing the most recent 10 out of 331 publications